Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01619020 · ClinicalTrials.gov registry record · NA
FlaxFx, A Research Study of the Effects of Flaxseed Lignans on Colon Health
A NA study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 66
- Enrollment target
NCT01619020 is a NA study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 66 participants.
The verdict
NCT01619020, a NA study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
Study Summary
Colorectal (CRC) cancer is the third most common cancer in the United States and its incidence is rising in younger populations. Diet seems to affect risk for CRC. Many parts of our diet are processed and modified by the microbes or bacteria in our gut. There are many different types of bacteria in our gut, each one of us has a "community" of different types and amounts of each type. When we eat flaxseeds, certain types of bacteria will process them - producing compounds that can then affect our body. How much of these compounds are produced by each person depends on the "community" of bacteria in the gut. Flaxseed and in certain nuts contain lignans, compounds that may have health benefits. Gut bacteria can convert the lignans into biologically active compounds that in animal models prevent the development of colon cancer. The investigators will study how these biologically active compounds affect colon cell-signaling pathways important to colorectal cancer risk. Results from our study will bridge the current knowledge from animal studies and epidemiologic studies and may help to inform approaches for future CRC prevention.
Interventions
- DIETARY_SUPPLEMENT Flaxseed Lignans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2012-10 |
| Est. Completion | 2017-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01619020
The ClinicalTrials.gov registry entry for NCT01619020 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Flaxseed Lignans is the first listed.
NCT01619020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01619020 about?
NCT01619020 is a clinical study titled "FlaxFx, A Research Study of the Effects of Flaxseed Lignans on Colon Health". Colorectal (CRC) cancer is the third most common cancer in the United States and its incidence is rising in younger populations. Diet seems to affect risk for CRC. Many parts of our diet are processed and modified by the microbes or bacteria in our gut. There are many different types of bacteria in...
What is the current status of trial NCT01619020?
This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2012-10. Estimated completion is 2017-08.
What interventions are being tested in trial NCT01619020?
The interventions under investigation include: Flaxseed Lignans (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01619020?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.